The US Food and Drug Administration (FDA) has extended the review period for United States-based Incyte's supplemental new drug application (NDA) for acute graft-versus-host disease (GVHD) treatment, Jakafi (ruxolitinib), it was reported on Friday.
24 May is the new Prescription Drug User Fee Act (PDUFA) target action date for Jakafi, which is for the treatment of patients with GVHD who have had an inadequate response to corticosteroids. The FDA has extended the action date to allow time to evaluate additional data provided by the company in response to the regulator's information requests. It has determined that submitted additional information is required to constitute a major amendment to the supplemental NDA, enabling it to extend the PUDFA goal date by three months.
In August 2018, Incyte submitted a supplemental NDA for ruxolitinib intended to treat patients with acute GVHD. Ruxolitinib secured priority review and breakthrough therapy designation from the US FDA.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial